title: Incorporation of crizotinib into the NCCN guidelines.
authors.affiliation: Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center.
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Riely
authors.forename: Jamie E
authors.initials: JE
authors.lastname: Chaft
authors.forename: Marc
authors.initials: M
authors.lastname: Ladanyi
authors.forename: Mark G
authors.initials: MG
authors.lastname: Kris
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D002986:Clinical Trials as Topic; D000077547:Crizotinib; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D008495:Medical Oncology / Q000331:legislation & jurisprudence* / Q000458:organization & administration / Q000639:trends; D025202:Molecular Diagnostic Techniques; D009154:Mutation / Q000502:physiology; D017410:Practice Guidelines as Topic; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011720:Pyrazoles / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D012955:Societies, Medical / Q000331:legislation & jurisprudence
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases